Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : Nearly a Quarter of New Yorkers Say They Won't Take Covid-19 Vaccine

11/24/2020 | 05:45am EST

By Jimmy Vielkind

Nearly a quarter of New Yorkers say they are unlikely to take a vaccine against the coronavirus when it becomes available, according to a poll released Tuesday.

Twenty-four percent of the 803 New York state voters surveyed by the Siena College Research Institute last week said they would either probably not or definitely not take a coronavirus vaccine if approved by the Food and Drug Administration.

The survey showed 35% said they definitely would take the vaccine, and 34% said they would probably take it. Three drugmakers have said in recent weeks that vaccines under their development were shown to be broadly effective in late-stage trials. On Friday Pfizer Inc. and partner BioNTech SE asked U.S. health regulators to permit emergency use of their two-shot vaccine.

Siena spokesman Steven Greenberg said the survey found support for the vaccine was "regardless of party, region, race, age, religion, gender, or even who they supported in the presidential election."

Even after approval, mass distribution will take months. New York Gov. Andrew Cuomo said in October that he expected people might be skeptical that FDA approvals could be influenced by President Trump, who has cheered the rapid deployment of a vaccine. The Democratic governor formed a panel of state experts to review any FDA determination, and he has criticized the Trump administration's vaccine-distribution plans.

The poll also found an increase in support for legalizing recreational marijuana for adults as well as letting New Yorkers bet on sports matches from their mobile devices. Both issues are on the table in Albany, as the state looks for ways to raise revenue to fill a projected $8.7 billion deficit in its coming fiscal year.

Sixty percent of voters surveyed support legalizing marijuana, and 32% oppose doing so -- up from a split of 55-40 in a February survey by Siena. Support for sports betting increased to 50% in the latest poll from 44% in February 2019.

This month's Siena survey has a margin of error of plus or minus 4.1 percentage points.

Write to Jimmy Vielkind at Jimmy.Vielkind@wsj.com

(END) Dow Jones Newswires

11-24-20 0544ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 2.86% 108.44 Delayed Quote.33.02%
PFIZER INC. 0.19% 36.55 Delayed Quote.-0.71%
All news about PFIZER INC.
03:26pTHE LATEST : Chicago opens restaurants, some bars with limits
01:09pUK vaccine roll-out speeds up but doctors want quicker second dose
12:49pAstraZeneca's Covid-19 Vaccine Shortfall Threatens EU Plans to Boost Inoculat..
11:41aPFIZER : UK doctors seek review of 12-week gap between vaccine doses
11:38aItaly PM says vaccine supply delays are serious contract violations
11:31aItaly pm conte says delays in vaccine supplies from pfizer, astrazeneca unacc..
06:06aTHE LATEST : N.Y. seniors, churches to get vaccine prep kits
01/22PFIZER : Provinces doing 'extraordinary' job to avoid wasting doses of COVID-19 ..
01/22Pfizer to supply 40M COVID-19 shots for poor countries
01/22ASTRAZENECA : to supply 31 mln COVID-19 shots to EU in first quarter, a 60% cut ..
More news
Financials (USD)
Sales 2020 48 216 M - -
Net income 2020 19 801 M - -
Net Debt 2020 43 531 M - -
P/E ratio 2020 11,8x
Yield 2020 3,98%
Capitalization 203 B 203 B -
EV / Sales 2020 5,12x
EV / Sales 2021 4,43x
Nbr of Employees 88 300
Free-Float 59,1%
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 41,93 $
Last Close Price 36,55 $
Spread / Highest target 45,0%
Spread / Average Target 14,7%
Spread / Lowest Target -1,50%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-0.71%203 159
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
ABBVIE INC.3.46%195 720